Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular (BIBLIOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03845543
Recruitment Status : Not yet recruiting
First Posted : February 19, 2019
Last Update Posted : February 19, 2019
Sponsor:
Information provided by (Responsible Party):
ID3 Medical

Brief Summary:
The BIBLIOS trial investigates the efficacy and safety of BTK treatment of patients suffering from critical limb ischemia (Rutherford 5) with the Luminor-14 Paclitaxel coated Percutaneous Transluminal Angioplasty Balloon catheter of iVascular. An expected total of 150 patients will be treated. Infrapopliteal lesions will be treated during this trial. The Paclitaxel eluting balloon Luminor-14 is designed for percutaneous transluminal angioplasties in which the balloon will dilate the artery upon inflation. The balloon is coated with Paclitaxel intended to avoid cellular proliferation. The drug is released by means of rapid inflation as to release a high dose in a short amount of time. Patients will be invited for a follow-up visit at 1, 6 and 12 months post-procedure. The primary efficacy endpoint is defined as freedom from major adverse limb events, defined as above the ankle target limb amputations or major reintervention to the target lesions at 6 months. The primary safety endpoint is freedom from major adverse limb event at 30 days. The secondary endpoints consist of functional flow in target vessel, freedom from clinically driven target lesion revascularisation, above the ankle amputation free survival and limb salvage at 6 and 12 months, and also procedural success, wound healing status and wound healing time.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Device: Luminor-14 Paclitaxel eluting balloon Not Applicable

Detailed Description:

The objective of this clinical investigation is to assess the safety and efficacy of the Luminor-14 DCB for the treatment of infrapopliteal lesions patients with critical limb ischemia.

The patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for long term follow-up. The patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.

Prior to the index procedure the following will be collected: an informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of acute limb ischemia (Rutherford category), the resting ankle-brachial index (ABI), life quality and if applicable a wound assessment.

During the procedure the guidewire will cross the entire study lesion after which the lesion will be assessed through angiography. A pre-dilatation with a standard non-drug-coated balloon will be performed followed by a dilatation of the lesion with a Luminor-14 balloon (iVascular). If dilatation was not successful (>30% stenosis, perforation, occlusive or flow limiting dissection) prolonged inflation should be attempted after which bail-out stenting with a non-drug-coated dedicated BTK stent is allowed in case of inadequate results.

The regular follow-up is necessary to monitor the condition of the patient and the results of the procedure. Patients will be invited on weekly follow-up, with special attention to wound healing status at each visit until the wound is completely healed. The other required follow-up visits are 1,6 and 12 months follow-ups. During these visit the following data will be collected: medication record, physical exam, wound assessment and healing status, quality of life, duplex ultrasound of target vessel and possible adverse events.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Belgian-Italian Prospective, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of BTK Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular of 150 Subjects With Critical Limb Ischemia
Estimated Study Start Date : February 2019
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angioplasty
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Luminor-14 paclitaxel eluting balloon
Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
Device: Luminor-14 Paclitaxel eluting balloon
Patients will be treated with the Luminor-14 paclitaxel eluting balloon




Primary Outcome Measures :
  1. Primary Efficacy Endpoint: Freedom from MALE [ Time Frame: 6 months post-procedure ]
    Freedom from major adverse limb events (MALE) defined as absence of above-ankle target limb amputation or major re-intervention to the target lesion(s) (i.e. new bypass graft, jump/interposition graft revision or thrombectomy/thrombolysis).

  2. Primary Safety Endpoint: Freedom from MALE [ Time Frame: 30 days post-procedure ]
    freedom from major adverse limb events defined as absence of above-ankle target limb amputation or major re-intervention to the target lesion(s) (i.e. new bypass graft, jump/interposition graft revision or thrombectomy/thrombolysis).

  3. Primary Safety Endpoint: Freedom from POD [ Time Frame: 30 days post-procedure ]
    No peri-operative death (POD) related to device, procedure or any other cause.


Secondary Outcome Measures :
  1. Target Vessel Functional Flow Assessment [ Time Frame: 6 and 12 months post-procedure ]
    Target vessel functional flow assessment defined as the presence of blood flow using duplex ultrasound. Evidence of no blood flow within the treated segment indicates loss of patency.

  2. Freedom from clinically driven target vessel revascularisation [ Time Frame: 6 and 12 months post-procedure ]
    Freedom from clinical driven target lesion revascularization defined as absence of any reintervention due to clinical deterioration, defined as a worsening of the patient's quality of life, reflected by the health-questionnaire (EQ-5D), worsening of the Rutherford category with minimal 1 class or worsening of wound status.

  3. Amputation free survival [ Time Frame: 6 and 12 months post-procedure ]
    Amputation free survival defined as alive with freedom from any above the ankle target limb amputation

  4. Limb salvage [ Time Frame: 6 and 12 months post-procedure ]
    Limb salvage is defined as freedom from any above the ankle target limb amputation

  5. Procedural success [ Time Frame: During index procedure ]
    Procedural success is defined as restoration of at least 1 below the knee artery with <30% residual stenosis in the final angiogram and outflow into the foot.

  6. Wound healing status [ Time Frame: 1, 6 and 12 months post-procedure ]

    Wound healing status is based on three parameters: the wound's diameter, the wound's depth and the % granulation tissue. These three parameters will be aggregated to one reported value using the modified Strauss wound classification scoring system.

    Score 2: >75% red granulation tissue / <1cm² wound size / wound depth to the skin or subcutaneous.

    Score 1: 50-75% red granulation tissue / 1-9cm² wound size / wound depth to muscle or tendon.

    Score 0: <50% red granulation tissue / >9cm² wound size / wound depth to the bone or joint


  7. Wound healing time [ Time Frame: 1, 6 and 12 months post-procedure ]
    Wound healing time is defined as the number of days needed for the wound to heal completely after the index procedure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or non-pregnant females ≥ 18 years of age at the time of consent. Females of childbearing potential have a negative pregnancy test <7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation. Female participants will be exempted from this requirement in case they are sterile, infertile or have been post-menopausal for at least 12 months
  • Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study. If the subject possesses the ability to understand and provide informed consent but due to physical inability, the subject cannot sign the informed consent form. An impartial witness may sign on behalf of the subject.
  • Willing to comply with all required follow-up visits
  • Rutherford Classification 5
  • Significant degree of stenosis >70% or chronic total occlusion (CTO)
  • Infrapopliteal lesion: P3 to the ankle-joint level (not below-the-ankle (BTA)); full length lesions or tandem lesions are allowed
  • Wound, Ischemia, foot Infection (WIfI) tissue loss grade 1-2 at baseline
  • WIfI foot infection grade of 0-2 at baseline
  • WIfI ischemia grade 2-3 at baseline
  • Estimated life expectancy ≥ 1 year
  • Multiple lesions can be treated if they are located in separate vessels per standard of care but only one (1) BTK vessel can be considered as the target lesion/vessel and need to be treated according the Clinical Investigation Protocol (CIP) guidelines.
  • Target vessel should give direct or indirect run-off to the foot (clearly documented in a foot/BTA angiogram)
  • Patients with in-flow lesions can be included if the lesions are treated successfully (residual stenosis ≤30%) with the same drug coated balloon (DCB) platform, bail-out stenting with a bare-metal stent (BMS).
  • Successful pre-dilatation of the target lesion (≤30% residual stenosis)

Exclusion Criteria:

  • Previous bypass graft in the target limb
  • Acute limb ischemia, defined as symptom onset during less than 14 days prior to the index procedure
  • Prior or planned above-the-ankle amputation to the target limb (this does not apply to ray amputation of ≤2 digits, simple digital amputations or ulcer debridement)
  • Previous DCB treatment in target vessel 6 months prior to index procedure
  • WIfI tissue loss grade 0 or 3 at baseline
  • WIfI foot infection grade 3 at baseline
  • WIfI ischemia grade 0-1 at baseline
  • Any systemic infection or immunocompromised state. Patients with an ascending infection/deep foot infection or abscess/white blood count (WBC)≥12.000/or febrile state or C reactive protein (CRP)>5mg/L
  • Endovascular or surgical procedure (not including diagnostic procedures, planned simple digital amputation or wound debridement) to the target limb within 30 days after the index procedure
  • Existing stent implant in the target vessel
  • Use of alternative therapies: atherectomy, cutting/scoring balloons, laser, …
  • Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80.000/μL or greater than 500.000/μL
  • Any subject in which antiplatelet, anticoagulant or thrombolytic therapy is contraindicated
  • Myocardial infarction, coronary thrombolysis or angina less than 30 days prior to the index procedure
  • History of stroke or transient ischemic attack (TIA) less than 90 days prior to the index procedure
  • Known hypersensitivity or contraindication to nickel-titanium alloy (Nitinol)
  • Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up
  • Patients on haemodialysis
  • Known hypersensitivity or allergy to contrast agents that cannot be medically managed
  • Known hypersensitivity or allergy to heparin, aspirin, paclitaxel, clopidogrel or other antiplatelet/anticoagulant therapies
  • Inadequate inflow lesion treatment (>30% residual stenosis)
  • Inadequate result of pre-dilatation (>30% residual stenosis)
  • Inadequate run-off to the foot
  • Bilateral BTK enrolment in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03845543


Contacts
Layout table for location contacts
Contact: Koen Deloose, MD +32(0) 52 25 25 17 koen.deloose@telenet.be
Contact: Merel Verschueren, MSc +32 (0) 52 25 27 45 office@id3medical.com

Locations
Layout table for location information
Belgium
OLV Ziekenhuis Aalst
Aalst, Oost-Vlaanderen, Belgium, 9300
Imelda Hospital
Bonheiden, Belgium, 2820
A.Z. Sint-Blasius
Dendermonde, Belgium, 9200
Z.O.L.
Genk, Belgium, 3600
Italy
I.R.C.C.S. MultiMedica
Milano, Milaan, Italy, 20099
Policlinico Abano Terme Not yet recruiting
Abano Terme, Padua, Italy, 1-35031
Contact: Marco Manzi, MD    + 39 049 211 8221    marco.manzi@casacura.it   
Sponsors and Collaborators
ID3 Medical
Investigators
Layout table for investigator information
Study Director: Koen Deloose, MD ID3 Medical

Layout table for additonal information
Responsible Party: ID3 Medical
ClinicalTrials.gov Identifier: NCT03845543     History of Changes
Other Study ID Numbers: BIBLIOS-Luminor14BTK
First Posted: February 19, 2019    Key Record Dates
Last Update Posted: February 19, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action